Quantcast

Dr. Reddy's Launches Imatinib Mesylate Tablets In U.S. - Quick Facts


Shutterstock photo


(RTTNews.com) - Dr. Reddy's Laboratories Ltd. (RDY) announced the launch of Imatinib Mesylate Tablets, USP, a therapeutic equivalent generic version of Gleevec Tablets in the U.S. market approved by the U.S. Food and Drug Administration.

According to IMS Health, Gleevec brand and generic had U.S. sales of approximately $868 million MAT for the most recent twelve months ending in July 2018. Gleevec is a trademark of Novartis Pharmaceuticals Corp.

Dr. Reddy's Imatinib Mesylate Tablets, USP is available in 100 mg 30 count bottle size and 400 mg 90 count bottle size.


Read the original article on RTTNews (http://www.rttnews.com/2939444/dr-reddy-s-launches-imatinib-mesylate-tablets-in-u-s-quick-facts.aspx)


For comments and feedback: contact editorial@rttnews.com




This article appears in: World Markets , Stocks , Economy



More from RTT News

Subscribe






See All RTT news











Research Brokers before you trade

Want to trade FX?